Recombinant COVID-19 Vaccine (HIPRA)

N/A

Report date: 2023/04/10 09:25:37

Base Information

Drug NameRecombinant COVID-19 Vaccine (HIPRA)
Drug Alias NameRecombinant Protein RBD Fusion Dimer VaccineCOVID-19 Vaccine HIPRACOVID-19 Vaccine (recombinant, adjuvanted)(HIPRA)Bimervax
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Genetically engineered subunit vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2023/03/30
Country/TerritoryVietnamItalySpain +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesHipra Scientific SLU
China Registration ClassN/A

Develop Information

Active CompaniesHipra Human Health SLHipra Scientific SLU
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A